

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain) May 8, 2025

OTHER RELEVANT INFORMATION

In accordance with the provisions set forth in Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), submits hereafter the press release regarding the grant obtained from the CDTI to drive pharmaceutical innovation within the framework of the European IPCEI Med4Cure project.

Yours faithfully,

Adolf Rousaud
Secretary non director of the Board of Directors
Laboratorio Reig Jofre SA

Barcelona (Spain), May 8, 2025

REIG JOFRE to receive €13 million from CDTI to drive pharmaceutical innovation within the framework of the European IPCEI Med4Cure project

- The grant, which represents more than 50% of the submitted project's value, underscores the strong alignment between REIG JOFRE's proposal and the strategic objectives of the European Med4Cure program.
- REIG JOFRE is driving the EMINTECH project as a strategic initiative to address two major global health challenges: antimicrobial resistance (AMR) and rare diseases. The project includes the development of advanced therapies, the integration of cutting-edge technologies, and the activation of an innovation ecosystem that accelerates technology transfer from the lab to the clinic and enables industrial scaling.
- IPCEI Med4Cure brings together over 175 entities from six European countries in an unprecedented collaboration within the pharmaceutical industry to promote health innovation, increase the sector's industrial resilience, and ensure the development of innovative manufacturing processes, as well as secure and sustainable access to essential therapeutic solutions.

REIG JOFRE, (BME:RIF), a pharmaceutical company listed on the Spanish continuous market, which develops, manufactures, distributes, and markets essential solutions, from prevention to the most critical healthcare situations, has been selected to receive **€13 million** grant from the **Centre for the Development of Industrial Technology (CDTI)**. This funding stems from the company's participation as an associated member in the first European IPCEI health project, **Med4Cure** (Important Project of Common European Interest).

The grant is part of the **Strategic Project for Economic Recovery and Transformation in Advanced Healthcare (PERTE for Health)** and represents more than 50% of the total value of the submitted project, highlighting its strong alignment with the strategic objectives of the program.

IPCEI Med4Cure is a major European initiative aimed at strengthening **Europe's health sovereignty** by boosting industrial and technological capabilities across the entire pharmaceutical value chain, from research and development to manufacturing and distribution.

A European commitment to the future of health

IPCEI Med4Cure brings together more than **175 entities from six European countries** in an unprecedented effort to foster health innovation, enhance the sector's industrial resilience, and guarantee secure and sustainable access to essential therapeutic solutions.

Within this framework, **REIG JOFRE is leading the EMINTECH project**, a €25 million strategic initiative running from 2023 to 2026, aimed at addressing two major global health challenges: **antimicrobial resistance (AMR)** and **rare diseases**. The project focuses on the development of advanced therapies, including **CAR-T** treatments, **gene therapy** platforms, phage-based solutions to combat **multidrug resistance**, and recombinant antibody treatments for **rare diseases**.

More information

Inma Santa-Pau – Director of Communications – isantapau@reigjofre.com

www.reigjofre.com



The company aims to transform how these pathologies are addressed by delivering more effective, personalized, and sustainable solutions. At the same time, EMINTECH aligns with REIG JOFRE's technological growth strategy, by integrating **state-of-the-art technology** to accelerate the development of new therapies and platforms, optimize production processes, expand patient access, minimize environmental impact, and strengthen its position as an **innovative leader in the European pharmaceutical landscape**.

Moving toward a more robust and resilient industry

Beyond its scientific scope, **EMINTECH aims to activate a collaborative innovation ecosystem**, in synergy with other European partners of the Med4Cure project, to accelerate technology transfer from the laboratory to clinical practice and enable its industrial scaling. Backed by this investment, the project will foster the creation of highly qualified jobs, strengthen public-private collaboration, and contribute to the development of a more sustainable pharmaceutical production model, aligned with the Sustainable Development Goals (SDGs).

"REIG JOFRE's participation in the IPCEI Med4Cure reflects our commitment to strengthening European healthcare autonomy through innovation that delivers real impact on health. This project enables us to accelerate the integration of scientific, industrial, and technological capabilities in critical areas such as antimicrobial resistance, biotechnology, and advanced therapies for rare diseases. It is undoubtedly a strategic step to consolidate our position as a key partner in the new European pharmaceutical model," stated **Ignasi Biosca, CEO of REIG JOFRE**.

This initiative positions REIG JOFRE as a key player in the transformation of the pharmaceutical development and production model in Europe, combining sustainability, innovation, and a commitment to people's well-being — with a clear purpose: to improve patients' quality of life, expand access to new therapies, and generate a tangible, positive impact on healthcare.

About REIG JOFRE

REIG JOFRE is a pharmaceutical company born out of a strong belief in making health universally accessible delivering everything from basic care solutions to the most innovative treatments to people around the world. To offer pioneering, high-impact solutions, the company relies on state-of-the-art production technology, ongoing collaboration with innovative companies, researchers, and startups, and sustained investment in R&D. Since 1929, REIG JOFRE has been researching, developing, manufacturing, and marketing pharmaceutical products essential to people's health across three major areas: Pharmaceutical Technologies (antibiotics and sterile injectable products for hospital use), Specialty Pharmacare (dermatology and osteoarticular therapies) y Consumer Healthcare (ENT and dietary supplements to support health and wellbeing).

REIG JOFRE operates four development and production centers in Europe, has in-house teams in Spain, France, Portugal, Belgium, Sweden, the UK, Poland, and the Czech Republic, and maintains a broad network of commercial partners in over 70 countries. With a workforce of more than 1,400 employees, REIG JOFRE closed 2024 with revenue of €339 million (+7% vs. 2023) and an EBITDA of €38 million (+8% vs. 2023). It is listed on the Spanish continuous market under the ticker RJF.